Retatrutide

10 mg

$89.99 CAD

An investigational peptide described in published research as acting at three receptors — GLP-1, GIP and glucagon — studied in a 2023 phase 2 trial.

Format: 10 mg
Use: Laboratory research

View cart

For laboratory research only · Not for human consumption

What is Retatrutide?

Retatrutide is a multi-receptor peptide agonist studied in metabolic research. It activates GLP-1, GIP and glucagon receptors; receptor activity and clinical outcomes are separate questions. “GLP-3” is not a receptor, and GLP-2 is a different target that this compound is not described as acting on.

Key concepts: GLP-1 receptor · GIP receptor · Glucagon receptor · Endpoint

How it works and what researchers study

Metabolic research of this kind uses randomized, placebo-controlled trials with defined populations and durations, measuring body-weight endpoints together with adverse events such as gastrointestinal symptoms and heart-rate changes.

What the evidence shows

A 2023 phase 2 randomized, placebo-controlled trial in 338 adults over 48 weeks reported lower body-weight outcomes in the study arms, along with gastrointestinal adverse events and heart-rate increases.

Limits of the evidence

That report is explicitly a 2023 phase 2 trial; it is not a statement about the current stage of any development programme.
We make no Canadian authorization claim. Authorization must be checked in the current Health Canada Drug Product Database record.
Trials study a specific manufactured medicine. This laboratory research vial is not that product.

References

Jastreboff AM et al. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. N Engl J Med. 2023. doi:10.1056/NEJMoa2301972 View source
Health Canada. Drug Product Database: the official list of drug products authorized for sale in Canada. View source

Compound science vs product quality

The research described here studied the compound under laboratory or clinical conditions. No cited paper or label tested a Proof Line Peptides vial. Product-level questions — identity, stated quantity and lot-matched documentation — are answered by records supplied with the material, not by published studies.

Questions about Retatrutide

How many receptors does retatrutide act on?: Three, as described in the published trial: the GLP-1, GIP and glucagon receptors.
Is it approved in Canada?: We do not claim any authorization. Check the specific current record in Health Canada’s Drug Product Database; a research material is in any case not the studied medicine.
Did the trial only report benefits?: No. It also reported gastrointestinal adverse events and increases in heart rate, which belong in any accurate summary.